ArticleJournal of medical virology2005
Recombinant protein-based ELISA and immuno-cytochemical assay for the diagnosis of SARS.
Article in Journal of medical virology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.Nature communications · 2020Pooled it
- Development of an ELISA for SARS-CoV-2 Detection Focusing on Antibodies against Nucleocapsid Protein.Archives of Razi Institute · 2025Article
- Article
- Development and validation of an enzyme-linked immunoassay kit for diagnosis and surveillance of COVID-19.Journal of clinical virology plus · 2022Article
- Recent advances in immunoassay technologies for the detection of human coronavirus infections.Frontiers in cellular and infection microbiology · 2022Review
- Serological assays and host antibody detection in coronavirus-related disease diagnosis.Archives of virology · 2021Review
- Benefits and limitations of serological assays in COVID-19 infection.The Indian journal of tuberculosis · 2020Review
- A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease.medRxiv : the preprint server for health sciences · 2020Article
- Detection of Antibodies Against Canine Circovirus in Naturally and Experimentally Infected Canines by Recombinant Capsid Enzyme-Linked Immunosorbent Assay.Frontiers in veterinary science · 2020Article
- Plant Molecular Farming as a Strategy Against COVID-19 - The Italian Perspective.Frontiers in plant science · 2020Article
- Antigen Production in Plant to Tackle Infectious Diseases Flare Up: The Case of SARS.Frontiers in plant science · 2016Article
- Serological assays for emerging coronaviruses: challenges and pitfalls.Virus research · 2014Review
- Immunoreactivity characterisation of the three structural regions of the human coronavirus OC43 nucleocapsid protein by Western blot: implications for the diagnosis of coronavirus infection.Journal of virological methods · 2013Article
- Autoantibodies against MMP-7 as a novel diagnostic biomarker in esophageal squamous cell carcinoma.World journal of gastroenterology · 2011Article
- Review
- Baculovirus expression of HCoV-OC43 nucleocapsid protein and development of a Western blot assay for detection of human antibodies against HCoV-OC43.Journal of virological methods · 2007Article
- Serum antibody response to Human papillomavirus (HPV) infections detected by a novel ELISA technique based on denatured recombinant HPV16 L1, L2, E4, E6 and E7 proteins.Infectious agents and cancer · 2006Article
- Generation of human antibody fragments recognizing distinct epitopes of the nucleocapsid (N) SARS-CoV protein using a phage display approach.BMC infectious diseases · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A new Coronavirus (SARS-CoV) is the aetiological agent of the severe acute respiratory syndrome (SARS). Because of the critical role played by serological assays for SARS diagnosis, an in-house ELISA based on SARS-CoV recombinant antigens was developed. The SARS-CoV nucleocapsid protein (N), three N fragments (N1, N2, and N3) and the intraviral domain of the membrane protein (M2) were cloned and expressed in Escherichia coli as histidine-tagged proteins. Six reference sera from SARS patients were used to detect virus-specific IgG in an ELISA using each recombinant protein as coating antigen. High-titre positive reactions were detected in all SARS positive sera. The specificity of the assay appears to be high as no positive reaction was detected in the sera of 20 healthy subjects and 73 patients with non-SARS, low-tract respiratory infections. Specific hyper-immune sera to SARS-CoV and the recombinant proteins, N, N1, N2, N3, and M2 were also generated in mice and rabbits. The specificity of these sera was confirmed by an immunocytochemical assay on biochips of SARS-CoV infected and uninfected cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.